Suneris Adds Four New Team Members in Key Roles

NEW YORK--(BUSINESS WIRE)--Suneris today announced the hiring of four individuals for key positions at the Brooklyn-based biotech company. The new team members, whose roles focus on research, regulatory affairs, operations and sales, will help support growing demand for VETIGEL™, a plant-based gel that stops severe bleeding in less than 12 seconds, as well as the development of future products.

The new hires appointed are Alison Douglas, PhD, research scientist; Andrew Fitzpatrick, director of manufacturing; Matthew Lewis, northeast regional sales manager; and Madeeha Syed, regulatory affairs specialist. With the addition of these new hires, the total employee count of Suneris, which was founded in 2010 by CEO Joe Landolina and CFO Isaac Miller, has grown to 25.

"Our focus at Suneris is finding uses for our existing technologies and developing new technologies that improve medical care and human health," Landolina said. "These important additions to our team will help us continue fulfilling our promise."

Joining Suneris as a research scientist following several years of experience researching fibrin hemostatics, Douglas will assist with the synthesis of biocompatible polymers for hemostasis and wound healing. Douglas, who previously worked as a research assistant at Georgia Institute of Technology and as a pre-doctoral fellow at the American Heart Association, will also handle lab management at Suneris.

Fitzpatrick joins Suneris from Celgene Cellular Therapeutics, where he served as director of manufacturing operations for four years. Fitzpatrick has also worked with Roche Molecular Systems and in scientific and compliance positions at Hoffman-La Roche Inc. In his role as director of manufacturing at Suneris, he will oversee the quality, safety and efficacy of all products, as well as compliance with FDA regulations.

As northeast regional sales manager, Lewis will manage a sales team supporting VETIGEL and other future products. Lewis joins Suneris from Royal Canin Veterinary Diets, where he served as district manager of veterinary sales. Previously, he worked in sales management positions for Lewis Medical Supplies and Lavi Industries.

In her role as regulatory affairs specialist at Suneris, Syed will help design aspects of the quality management system and support regulatory submissions. Syed joins Suneris from Stryker Orthopaedics, where she worked as a regulatory affairs specialist. Previously, she worked with the Integra LifeSciences Corporation and GlaxoSmithKline.

"Each of our new team members adds industry expertise to critical functions within Suneris," Landolina said. "We couldn't be happier that they are on board as we continue to expand and evolve."

ABOUT SUNERIS

Suneris is a biotech company focused on inventive emergency medical technologies that can improve patient care and save lives. Suneris' premier product, VETIGEL™, is designed exclusively for veterinarians to stop moderate to traumatic bleeding on internal or external wounds. Future human-use potential for Suneris' gel technology covers many fields, including military, emergency medicine and human surgical use. For more information, please visit suneris.co.

Contacts
Edelman
Rachel Edery, 212-729-2182
[email protected]

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…